Analytical evaluation of the Dade Behring Dimension RxL automated N-terminal proBNP (NT-proBNP) method and comparison with the Roche Elecsys 2010

被引:37
作者
Di Serio, F [1 ]
Ruggieri, V [1 ]
Varraso, L [1 ]
De Sario, R [1 ]
Mastrorilli, A [1 ]
Pansini, N [1 ]
机构
[1] Policlin Bari, Unita Operat Patol Clin 1, Bari, Italy
关键词
brain natriuretic peptide (BNP); heart failure; natriuretic peptides; N-terminal proBNP (NTproBNP);
D O I
10.1515/CCLM.2005.217
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Methods to quantify B-type natriuretic peptide (BNP) and N-terminal-propeptide (NT-proBNP) in plasma or serum samples are well established. We assessed the analytical performance of the Dimension RxL NT-proBNP method (Dade-Behring). Evaluation of different sample types was carried out. Controls and heparin plasma pools were used to determine the detection limit, precision, and linearity. Sample stability and the effect of interfering substances on the NT-proBNP concentrations were evaluated. Agreement between Dimension RxL and Elecsys 2010 (Roche Diagnostics) NT-proBNP methods was assessed. The influence of age and sex on NT-proBNP concentrations was evaluated in healthy subjects. Heparin plasma should be the matrix of choice. The detection limit was 2.0 ng/L. The total imprecision was 2.6-3.6% for concentrations from 231 to 9471 ng/L; mean NT-proBNP concentrations of 21 and 15 ng/L were associated with coefficients of variation of 9.9% and 14.7%, respectively. The method was linear up to 32,650 ng/L. There was no effect of temperature, freeze-thaw cycles and interfering substances. A bias was detected when Dimension RxL and Elecsys 2010 NT-proBNP methods were compared. Age and sex were significantly and independently related to N proBNP concentrations. The Dimension RxL NT-proBNP method, like the Elecsys 2010, is suitable for routine use in the diagnosis of heart failure.
引用
收藏
页码:1263 / 1273
页数:11
相关论文
共 38 条
  • [1] *AG HLTH CAR POL R, 1994, HEART FAIL EV CAR PA
  • [2] [Anonymous], 2005, HEART DIS STROKE STA
  • [3] Quality specifications for B-type natriuretic peptide assays
    Apple, FS
    Panteghini, M
    Ravkilde, J
    Mair, J
    Wu, AHB
    Tate, J
    Pagani, F
    Christenson, RH
    Jaffe, AS
    [J]. CLINICAL CHEMISTRY, 2005, 51 (03) : 486 - 493
  • [4] STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT
    BLAND, JM
    ALTMAN, DG
    [J]. LANCET, 1986, 1 (8476) : 307 - 310
  • [5] High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure
    Bruins, S
    Fokkema, MR
    Römer, JWP
    DeJongste, MJL
    Van der Dijs, FPL
    Van den Ouewland, JMW
    Muskiet, FAJ
    [J]. CLINICAL CHEMISTRY, 2004, 50 (11) : 2052 - 2058
  • [6] Analytical performance and diagnostic accuracy of immunometric assays for the measurement of plasma B-type natriuretic peptide (BNP) and N-terminal proBNP
    Clerico, A
    Prontera, C
    Emdin, M
    Passino, C
    Storti, S
    Poletti, R
    Zyw, L
    Zucchelli, GC
    [J]. CLINICAL CHEMISTRY, 2005, 51 (02) : 445 - 447
  • [7] Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: A review
    Clerico, A
    Emdin, M
    [J]. CLINICAL CHEMISTRY, 2004, 50 (01) : 33 - 50
  • [8] The circulating levels of cardiac natriuretic hormones in healthy adults: Effects of age and sex
    Clerico, A
    Del Ry, S
    Maffei, S
    Prontera, C
    Emdin, M
    Giannessi, D
    [J]. CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2002, 40 (04) : 371 - 377
  • [9] Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys™ 1010 and 2010 analysers
    Collinson, PO
    Barnes, SC
    Gaze, DC
    Galasko, G
    Lahiri, A
    Senior, R
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) : 365 - 368
  • [10] Doust JA, 2005, BMJ-BRIT MED J, V330, P1